These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242 [TBL] [Abstract][Full Text] [Related]
4. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062 [TBL] [Abstract][Full Text] [Related]
5. Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women. Lafage-Proust MH Kidney Int; 2008 Sep; 74(5):557-9. PubMed ID: 18709026 [TBL] [Abstract][Full Text] [Related]
6. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study. Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638 [TBL] [Abstract][Full Text] [Related]
7. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project]. Dalle Carbonare L; Bertoldo F; Lo Cascio V Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189 [TBL] [Abstract][Full Text] [Related]
8. Annual zoledronic acid for osteoporosis. BMJ Group Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701 [TBL] [Abstract][Full Text] [Related]
10. Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid. Cha YJ; Lee YJ Int J Clin Pharmacol Ther; 2013 Apr; 51(4):274-82. PubMed ID: 23357846 [TBL] [Abstract][Full Text] [Related]
11. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667 [TBL] [Abstract][Full Text] [Related]
12. Yearly zoledronic acid in postmenopausal osteoporosis. Chang JT N Engl J Med; 2007 Aug; 357(7):713-4; author reply 714-5. PubMed ID: 17703528 [No Abstract] [Full Text] [Related]
13. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis. Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098 [TBL] [Abstract][Full Text] [Related]
14. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid]. Geusens PP; Lems WF Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1445-8. PubMed ID: 17633971 [TBL] [Abstract][Full Text] [Related]
15. Effect of zoledronic acid therapy on postmenopausal osteoporosis between the Uighur and Han population in Xinjiang: An open-label, long-term safety and efficacy study. Xu W; Xiang C; Wang H; Yuan H; Zhao X; Xiao X J Clin Pharm Ther; 2018 Jun; 43(3):336-341. PubMed ID: 29114907 [TBL] [Abstract][Full Text] [Related]
16. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. Lambrinoudaki I; Vlachou S; Galapi F; Papadimitriou D; Papadias K Clin Interv Aging; 2008; 3(3):445-51. PubMed ID: 18982915 [TBL] [Abstract][Full Text] [Related]
17. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density. Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066 [TBL] [Abstract][Full Text] [Related]
18. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density. Chávez-Valencia V; Arce-Salinas CA; Espinosa-Ortega F J Clin Densitom; 2014; 17(4):484-9. PubMed ID: 24613450 [TBL] [Abstract][Full Text] [Related]
19. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Silverman SL; Kriegman A; Goncalves J; Kianifard F; Carlson T; Leary E Osteoporos Int; 2011 Aug; 22(8):2337-45. PubMed ID: 21116816 [TBL] [Abstract][Full Text] [Related]
20. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis. Ding Y; Zeng JC; Yin F; Zhang CL; Zhang Y; Li SX; Liu X; Zhang C; Xue QY; Lin H; Pei FX Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]